Materias dentro de su búsqueda.
Mostrando 32,381 - 32,400 Resultados de 33,745 Para Buscar '"interferón"', tiempo de consulta: 0.60s Limitar resultados
  1. 32381
    “…Human umbilical vein endothelial cells (HUVECs) were incubated with ICs, positive and negative controls. mRNA levels of endothelin-1 (et-1), collagenIα1 (colIα1), interferon (IFN)-α, and IFN-β were investigated by real-time PCR; et-1 and il-6 mRNA levels were assessed after pre-treatment with bafilomycin. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis
  2. 32382
    “…Plus rarement, elles sont un signe d’interféronopathie, groupe de maladie monogénique caractérisé par une forte production d’interferon de type 1 (INF-1). Les engelures ont constitué la plus fréquente des manifestations cutanées associées à la COVID-19. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Engelures associées à la COVID-19 : comparaison avec le lupus engelure et relation avec le SARS-CoV-2
  3. 32383
    “…INTERVENTION AND COMPARATOR: In the first stage, three subjects are given ixekizumab (“Taltz”) (80 mg/ml, 160 mg as a single hypodermic injection) and antiviral therapy (α-interferon (administer 5 million U by aerosol inhalation twice daily), lopinavir/ritonavir (administer 100mg by mouth twice daily, for the course of therapy no more than 10 days), chloroquine (administer 500mg by mouth twice daily, for the course of therapy no more than 10 days), ribavirin (administer 500mg by intravenous injection two to three times a day, for the course of therapy no more than 10 days), or arbidol (administer 200mg by mouth three times a day, for the course of therapy no more than 10 days), but not more than 3 types). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial
  4. 32384
    “…Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19·5 (95% CI 16·8–22·7) and 18·3 (14·4–23·3) in participants receiving 1 × 10(11) and 5 × 10(10) viral particles, respectively. Specific interferon γ enzyme-linked immunospot assay responses post vaccination were observed in 227 (90%, 95% CI 85–93) of 253 and 113 (88%, 81–92) of 129 participants in the 1 × 10(11) and 5 × 10(10) viral particles dose groups, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
  5. 32385
    “…Chez l’adulte, il existe une surexpression du CD169 sur les monocytes, qui est un récepteur activé par le système interféron de type 1. Cette surexpression serait corrélée à la charge virale et pourrait constituer un nouveau biomarqueur pour les patients atteints du SARS-CoV-2. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Étude de l’expression du CD169 sur les monocytes comme biomarqueurs des infections virales notamment le SARS-CoV-2 chez l’enfant
  6. 32386
    “…Most patients received anti-viral treatment with either hydroxichloroquine (47 patients, 54%), lopinavir/ritonavir (34 patients, 39%), remdesivir (5, 4%) and/or other treatments including azythromicin or interferon. 23 patients (26%) received anticytokine treatment with tocilizumab (15, 17%) and/or anakinra (8, 9%) and 27 patients (31%) received steroids. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of Sars-Cov-2 Infection in Hematopoietic Transplant Patients: Experience from the Madrid Group
  7. 32387
    “…Patients with a treatment history of anti-CD20-depleting agents (rituximab or ocrelizumab) and with no previous history of SARS-CoV-2 infection were enrolled between April 26 and June 30, 2021, for analysis of humoral and cell-mediated immune responses (by interferon-γ [IFNγ] release assay) at least 4 weeks after completing vaccination against SARS-CoV-2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
  8. 32388
    “…Participants were randomly assigned (1:1:1:1:1) to receive standard of care alone or in combination with remdesivir, lopinavir–ritonavir, lopinavir–ritonavir and interferon beta-1a, or hydroxychloroquine. Randomisation used computer-generated blocks of various sizes; it was stratified on severity of disease at inclusion and on European administrative region. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
  9. 32389
    por Angyal, Adrienn, Longet, Stephanie, Moore, Shona C, Payne, Rebecca P, Harding, Adam, Tipton, Tom, Rongkard, Patpong, Ali, Mohammad, Hering, Luisa M, Meardon, Naomi, Austin, James, Brown, Rebecca, Skelly, Donal, Gillson, Natalie, Dobson, Sue L, Cross, Andrew, Sandhar, Gurjinder, Kilby, Jonathan A, Tyerman, Jessica K, Nicols, Alexander R, Spegarova, Jarmila S, Mehta, Hema, Hornsby, Hailey, Whitham, Rachel, Conlon, Christopher P, Jeffery, Katie, Goulder, Philip, Frater, John, Dold, Christina, Pace, Matthew, Ogbe, Ane, Brown, Helen, Ansari, M Azim, Adland, Emily, Brown, Anthony, Chand, Meera, Shields, Adrian, Matthews, Philippa C, Hopkins, Susan, Hall, Victoria, James, William, Rowland-Jones, Sarah L, Klenerman, Paul, Dunachie, Susanna, Richter, Alex, Duncan, Christopher J A, Barnes, Eleanor, Carroll, Miles, Turtle, Lance, de Silva, Thushan I
    Publicado 2022
    “…We measured spike-specific IgG antibodies and quantified T-cell responses by interferon-γ enzyme-linked immunospot assay in all participants where samples were available at the time of analysis, comparing SARS-CoV-2-naive individuals to those with previous infection. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
  10. 32390
    “…Aim of the study: To investigate T-cell response determined by interferon gamma (IFNγ) secretion in patients with CLL following BNT162b mRNA Covid-19 vaccine, in comparison with serologic response. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cellular Immune Responses to BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
  11. 32391
    “…Post-prime and post-boost four times increase in spike-specific or nucleocapsid-specific T cells secreting interferon-γ was measured in 48 (98%; 95% CI 89–100) of 49 participants who received at least one dose of COH04S1 and provided a sample for immunological analysis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial
  12. 32392
    por Nguyen, Thuy P., Do, Quyet, Phan, Lan T., Dinh, Duc V., Khong, Hiep, Hoang, Luong V., Nguyen, Thuong V., Pham, Hung N., Chu, Men V., Nguyen, Toan T., Pham, Quang D., Le, Tri M., Trang, Tuyen N.T., Dinh, Thanh T., Vo, Thuong V., Vu, Thao T., Nguyen, Quynh B.P., Phan, Vuong T., Nguyen, Luong V., Nguyen, Giang T., Tran, Phong M., Nghiem, Thuan D., Tran, Tien V., Nguyen, Tien G., Tran, Tuynh Q., Nguyen, Linh T., Do, Anh T., Nguyen, Dung D., Ho, Son A., Nguyen, Viet T., Pham, Dung T., Tran, Hieu B., Vu, Son T., Hoang, Su X., Do, Trung M., Nguyen, Xuan T., Le, Giang Q., Tran, Ton, Cao, Thang M., Dao, Huy M., Nguyen, Thao T.T., Doan, Uyen Y, Le, Vy T.T., Tran, Linh P., Nguyen, Ngoc M., Nguyen, Ngoc T., Pham, Hang T.T., Nguyen, Quan H., Nguyen, Hieu T., Nguyen, Hang L.K., Tran, Vinh T., Tran, Mai T.N., Nguyen, Truc T.T., Ha, Phat T., Huynh, Hieu T., Nguyen, Khanh D., Thuan, Ung T., Doan, Chung C., Do, Si M.
    Publicado 2022
    “…Secondary outcomes were surrogate virus neutralisation (inhibition percentage), wild-type SARS-CoV-2 neutralisation (dilution fold), and T-cell responses by intracellular staining for interferon gamma (IFNg). Anti-S IgG and neutralising antibody levels were compared with convalescent serum samples from symptomatic Covid-19 patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial
  13. 32393
    por Cao, Jing, Yuan, Lei
    Publicado 2022
    “…The 10 hub genes in the upregulated network [G Protein Subunit Alpha I2 (GNAI2), G Protein Subunit Alpha I1 (GNAI1), G Protein Subunit Alpha I3 (GNAI3), G Protein Subunit Gamma 2 (GNG2), G Protein Subunit Beta 1 (GNB1), G Protein Subunit Gamma 13 (GNG13), G Protein Subunit Gamma Transducin 1 (GNGT1), G Protein Subunit Gamma 12 (GNG12), AKT Serine/Threonine Kinase 1 (AKT1) and GNAS Complex Locus (GNAS)] and the 10 hub genes in the downregulated network [Nucleotide-Binding Oligomerization Domain Containing Protein 2 (NOD2), Receptor-Interacting Serine/Threonine Kinase 2 (RIPK2), Nucleotide-Binding Oligomerization Domain Containing Protein 1 (NOD1), Mitochondrial Antiviral Signaling Protein (MAVS), Autophagy Related 16-Like 1 (ATG16L1), Interferon Induced With Helicase C Domain 1 (IFIH1), Autophagy Related 5 (ATG5), TANK-Binding Kinase 1 (TBK1), Caspase Recruitment Domain Family Member 9 (CARD9), and von Willebrand factor (VWF)] were screened using cytoHubba. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Identification of key genes for hypertrophic cardiomyopathy using integrated network analysis of differential lncRNA and gene expression
  14. 32394
    por Matuozzo, Daniela, Talouarn, Estelle, Marchal, Astrid, Zhang, Peng, Manry, Jeremy, Seeleuthner, Yoann, Zhang, Yu, Bolze, Alexandre, Chaldebas, Matthieu, Milisavljevic, Baptiste, Gervais, Adrian, Bastard, Paul, Asano, Takaki, Bizien, Lucy, Barzaghi, Federica, Abolhassani, Hassan, Abou Tayoun, Ahmad, Aiuti, Alessandro, Alavi Darazam, Ilad, Allende, Luis M., Alonso-Arias, Rebeca, Arias, Andrés Augusto, Aytekin, Gokhan, Bergman, Peter, Bondesan, Simone, Bryceson, Yenan T., Bustos, Ingrid G., Cabrera-Marante, Oscar, Carcel, Sheila, Carrera, Paola, Casari, Giorgio, Chaïbi, Khalil, Colobran, Roger, Condino-Neto, Antonio, Covill, Laura E., Delmonte, Ottavia M., El Zein, Loubna, Flores, Carlos, Gregersen, Peter K., Gut, Marta, Haerynck, Filomeen, Halwani, Rabih, Hancerli, Selda, Hammarström, Lennart, Hatipoğlu, Nevin, Karbuz, Adem, Keles, Sevgi, Kyheng, Christèle, Leon-Lopez, Rafael, Franco, Jose Luis, Mansouri, Davood, Martinez-Picado, Javier, Metin Akcan, Ozge, Migeotte, Isabelle, Morange, Pierre-Emmanuel, Morelle, Guillaume, Martin-Nalda, Andrea, Novelli, Giuseppe, Novelli, Antonio, Ozcelik, Tayfun, Palabiyik, Figen, Pan-Hammarström, Qiang, de Diego, Rebeca Pérez, Planas-Serra, Laura, Pleguezuelo, Daniel E., Prando, Carolina, Pujol, Aurora, Reyes, Luis Felipe, Rivière, Jacques G., Rodriguez-Gallego, Carlos, Rojas, Julian, Rovere-Querini, Patrizia, Schlüter, Agatha, Shahrooei, Mohammad, Sobh, Ali, Soler-Palacin, Pere, Tandjaoui-Lambiotte, Yacine, Tipu, Imran, Tresoldi, Cristina, Troya, Jesus, van de Beek, Diederik, Zatz, Mayana, Zawadzki, Pawel, Al-Muhsen, Saleh Zaid, Alosaimi, Mohammed Faraj, Alsohime, Fahad M., Baris-Feldman, Hagit, Butte, Manish J., Constantinescu, Stefan N., Cooper, Megan A., Dalgard, Clifton L., Fellay, Jacques, Heath, James R., Lau, Yu-Lung, Lifton, Richard P., Maniatis, Tom, Mogensen, Trine H., von Bernuth, Horst, Lermine, Alban, Vidaud, Michel, Boland, Anne, Deleuze, Jean-François, Nussbaum, Robert, Kahn-Kirby, Amanda, Mentre, France, Tubiana, Sarah, Gorochov, Guy, Tubach, Florence, Hausfater, Pierre, Meyts, Isabelle, Zhang, Shen-Ying, Puel, Anne, Notarangelo, Luigi D., Boisson-Dupuis, Stephanie, Su, Helen C., Boisson, Bertrand, Jouanguy, Emmanuelle, Casanova, Jean-Laurent, Zhang, Qian, Abel, Laurent, Cobat, Aurélie
    Publicado 2023
    “…BACKGROUND: We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7-dependent type I interferon (IFN) immunity or to autoantibodies against type I IFN, account for 15–20% of cases of life-threatening COVID-19 in unvaccinated patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
  15. 32395
    “…Underlying immune defects does seem to be independent risk factors for severe SARS-CoV-2 infection in children with IEIs, a number of children with SCID and CID were reported to have prolonged infections–though the number of patients is small–but especially immune dysregulation diseases (XLP1 and XLP2) and innate immunodeficiencies impairing type I interferon signalling (IFNAR1, IFNAR2 and TBK1). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13223-023-00831-1.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Severity of SARS-CoV-2 infection in children with inborn errors of immunity (primary immunodeficiencies): a systematic review
  16. 32396
    “…Currently the only recognised JAK inhibitor for the treatment of sarcoidosis is tofacitinib as it inhibits both interferon by JAK1 and G-CSF through JAK2/3. STAT1 has been isolated during immunohistological analysis of skin lesions in sarcoidosis which is inhibited by tofacitinib and forms the basis of its use in cutaneous sarcoidosis. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P15 JAKi of all trades
  17. 32397
    “…Chest X-ray demonstrated diffuse widespread ∼3-4cm opacifications in keeping with lung nodules. Interferon gamma release assay testing was indeterminate. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P24 TB or not TB? A case of severe multi-organ erosive rheumatoid arthritis in a Ukrainian refugee
  18. 32398
    “…T-cell immunity was evaluated by interferon-γ-linked enzyme-linked immune absorbent spot assay. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
  19. 32399
    “…The rationale is that TPE can remove interleukins-3, 6, 8, 10, interferon-gamma and tumor necrosis factor-alpha. Thus, it may reduce the cytokine release syndrome associated with fulminant COVID-19 disease. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol
  20. 32400
    “…In analyses including observational studies, interferon-alpha (OR 0.05, 95% CI 0.01 to 0.39, p = 0.004), itolizumab (OR 0.10, 95% CI 0.01 to 0.92, p = 0.042), sofosbuvir plus daclatasvir (OR 0.26, 95% CI 0.07 to 0.88, p = 0.030), anakinra (OR 0.30, 95% CI 0.11 to 0.82, p = 0.019), tocilizumab (OR 0.43, 95% CI 0.30 to 0.60, p < 0.001), and convalescent plasma (OR 0.48, 95% CI 0.24 to 0.96, p = 0.038) were associated with reduced mortality rate in non-ICU setting, while high-dose intravenous immunoglobulin (IVIG) (OR 0.13, 95% CI 0.03 to 0.49, p = 0.003), ivermectin (OR 0.15, 95% CI 0.04 to 0.57, p = 0.005), and tocilizumab (OR 0.62, 95% CI 0.42 to 0.90, p = 0.012) were associated with reduced mortality rate in critically ill patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis
Herramientas de búsqueda: RSS